EMERGENCY CONTRACEPTION: AN UPDATED REVIEW

M. Guida¹
M.L. Marra¹
V. Palatucci¹
R. Pascale¹
F. Visconti¹
F. Zullo¹

¹Department of Obstetrics & Gynecology, University of Salerno, Italy

Summary

Emergency contraception is a common practice now. Many categories of drugs are marketed with modifications in dosage, in combination and even in the timing of administration. Recent re-analysis suggests that there is still no uniformity of opinion on the actual mechanism of action and this has often fueled the ethical controversy. This review analyzes the most common emergency contraception drugs: levonorgestrel, mifepristone and ulipristal acetate about their action underlining that the hormonal products, when used in emergency contraception, play different roles depending on the phase of the menstrual cycle during which they are administered. This review aims to examine rigorously the most accredited literature to verify if a evidence-based uniformity of opinions has been achieved about the biological effects of hormones administered after the sexual intercourse.

Key words: emergency contraception, levonorgestrel, mifepristone, ulipristal acetate.
1-Introduction

Since the second half of the last century, hormonal products have began to be used for contraceptive purposes as a social consequence of a real “cultural revolution” [1]. The role of the hormonal contraception has been crucial to foster women's empowerment and gender equality [2,3]. Moreover, unlike other categories of drugs, the contraceptive products (generally referred to as “the pill”) have undergone continuous modifications in dosage, combination and even in the timing of drug administration – today it is administered also after sexual intercourses [4,5]. Nowadays we can state that hormonal contraception can be prescribed to healthy women of all ages [6]. Nevertheless, these progresses have initially met harsh resistances from the doctors themselves mainly for ethical and religious reasons especially when cases may occur that hormonal products would damage embryo and not only avoid conception. This is still a highly topical issue especially when considering the so-called “emergency contraception” that makes use of hormonal products only after a sexual intercourse. Scientific literature and international cultural debate have not yet reached a common view on the actual mechanism of action of some hormone molecules when administered after sexual intercourse. It is clear that the ethical (and thus religious) judgement cannot neglect the strict and rigorous awareness of the effects that the hormonal emergency contraception causes before and after conception, that is damage to the embryo or before the embryo starts to develop. Bitter controversy have aroused about this delicate issue. This review wants to underline that very often there is no clear distinction between the legal aspects and the ethical aspects of this issue. On the contrary, we deem that the legal aspect of the use of emergency contraception should be appraised according to the law in force in each country. Ethical facets do not take into consideration the legal frameworks, indeed they need a moral evaluation. In short, it only answers the question about the possible damage that these hormones may cause on the embryo which a lot of religions consider untouchable. It goes without saying that those who are in favour of intentional abortion (usually included in the legislation of many countries) will see no harm in emergency contraception taking place at the very early phases of the embryo development and will consider this opportunity as an improvement in the health services offered to the women who do not intend to carry on an unexpected pregnancy. It is nonetheless true that those who do administer hormones to avoid conception (generally referred to as “contraception”) might not administer hormones after conception (generally referred to as “emergency contraception”).

1.1History

Over eighty years have passed since the first attempts to develop a method that interferes with the events subsequent to sexual intercourse. Since 1920 it’s known that estrogen -when administered early- could interfere with pregnancy; the first case reported in the 1960s literature is about a raped girl in a presumably ovulatory period, who was submitted to estrogen administration [7]. Since then, an increasing
number of women was treated with high doses of conjugated estrogens, until -in the early 70s- the combined administration of estrogen and progestin was proposed. In 1972, Yuzpe, a Canadian researcher published the first experimental data, using the self-called method [8]; meanwhile, trials with only made progestin drugs began [9], and in the late 70s the intrauterine device between the forms of “emergency contraception” [10] was introduced; recently also the mifepristone or RU486[11] have been used for this purpose.

### 1.2 Definitions

Even the definition itself has aroused a lot of controversies about the use of emergency contraception. There are at least two main schools of thought: those who believe abortion only occurs after embryo have implanted into the uterus (they state that the hormones administered before implantation can be considered “contraception”) and those who believe that also the interruption of the embryonic development, before implantation, represents an abortion (they claim that the hormones administered after the conception are “abortion”).

It's very important to define the beginning of pregnancy; on one side, the principal scientific associations believe that it begins with the egg’s implantation [12-16]; in the early 70s the ACOG (American College of Obstetricians and Gynecologists) has redefined the concept of pregnancy; the term “pregnancy” refers to the period between the implantation of the embryo in the uterus and childbirth [17]. On the other side, other authors believe that pregnancy starts when oocyty is fertilized, assuming that the embryo is “born” in that stage [18,19].

To better understand the difficulties rising from the definition of “contraception” we must remember that in humans (assuming an average duration of the menstrual cycle of 28 days) the normal length of pregnancy is 40 weeks, totaling 280 days, calculated from the starting day of the last menstrual period. Instead, considering the ovulation day, the normal duration of the conception’s product development is 38 weeks, equal to 266 days. In this case, therefore, the term “pregnancy” includes not only the period from fertilization to birth, but also the 15 days preceding ovulation, since the reference empirically detectable is the last menstrual period [20].

Considering these dissimilar points of view, a differentiation have to be made between the concept of “emergency contraception”, “interception” and “abortion”.

Emergency Contraception -according to the WHO and the ACOG- is defined as all these methods that can give to the women a no risky way to prevent an unwanted pregnancy after unprotected intercourse, or in case of contraceptive failure, when it is used within 120 hours from unprotected intercourse [16,21].

Instead, if we consider begin of the pregnancy when the egg is fertilized, the use of post-coital methods may fall under the definition of abortion [18,19].

Even as regards the definitions of abortion, there are different points of view.

The definition suggested by WHO considers as abortion both the pregnancy terminated within 20 weeks of gestation and a born weighting less than 500g fetus; in other words, the process of gestation is included between the period when the zygote attaches itself to the uterine wall (about 14 days after conception), and the time when the fetus is capable of surviving on its own [21,22,23].

Others consider abortion as any method that acts by interrupting the pregnancy from the moment the egg is fertilized [24,25,26].

Interception is different from abortion because of the moment in which the contraceptive methods can interfere with the blastocyst implanting in the uterus [27,28,29].

Following some authors, the term “interception” corresponds to the term “abortion” [30].
1.3 Drugs

As a general rule “emergency contraception” can be achieved using the drugs reported in the following table [Tab1]. This review aims at studying the most recent drugs around which the controversy about the actual mechanism of action has developed.

2- Levonorgestrel (LNG)

The trade name of levonorgestrel is norlevo, levonelle, lonel

2.1 Introduction

Levonorgestrel is a second generation synthetic progestogen used as an active ingredient in some hormonal contraceptives; chemically, it is a hormonally active levorotatory enantiomer of the racemic mixture norgestrel. It is a progestin derived from 19-nortestosterone [31]. LNG represents the active isomer of norgestrel and is administered orally or delivered either via an intrauterine device or from subdermal implants [32]. The levonorgestrel-only pill is commonly used for emergency contraception (EC), a back-up method for contraceptive failure which a woman can use within a few days of an unprotected intercourse to prevent an unwanted pregnancy. The standard regimen is to be administered within 72 h (can be extended to 120 h) of an unprotected intercourse, 1.5 mg either as a single dose or in two doses 12 h apart [33]. This regimen is estimated to reduce a woman’s risk of becoming pregnant by 57–93% [34-38]. As EC the levonorgestrel intrauterine system and copper intrauterine device [39] can be inserted up to five days after unprotected intercourse. The levonorgestrel intrauterine system presents a lower incidence of pelvic inflammation and irregular bleeding. A disadvantage of this type of contraception is that it can’t be used in women with vaginal infections, sexual infections and pelvic inflammatory disease.

2.2 Mechanism of action

There is wide controversy about the possible mechanism throughout the LNG, used for emergency oral contraception, prevents pregnancy; this is still an open question [40-44]. We considered both Levonorgestrel impact on ovulation and on endometrium.

2.2.1 Impact on ovulation

Hapanagama et al. [45] studied twelve healthy women with regular cycles.
They administered LNG in the fertile period that was identified considering changes in the hormones levels of oestrone - 3 - glucuronide (E3G), a urinary metabolite of oestradiol and LH, evaluated with a monitoring system that includes disposable test sticks and a hand-held monitor.

Six women received LNG in the first study cycle and placebo in the third study cycle; the remaining six women received placebo in the first study cycle and LNG in the third study cycle.

The second study cycle was a washout phase for all women during which they also received placebo.

Seven women had apparently normal ovulatory cycles after taking LNG; five of them took LNG on the day before the LH surge and one on the day of the surge. In the four women in whom the LH peak and ovulation was delayed, the LNG was taken within three days of the predicted LH peak; one woman did not ovulate at all despite having an LH surge two days after taking LNG.

This seven women, who apparently ovulated normally, had a reduced total luteal LH and a shortened luteal phase; in fact, basal levels of LH are essential for the normal secretory function of the corpus luteum.

This study suggests that LNG - taken immediately before ovulation - acts as an emergency contraceptive by delaying or preventing ovulation.

Durand et al. [46] studied forty-five healthy women with regular menstrual cycles.

All participants were admitted during the first ten days of their menstrual cycle and after a control cycle, were randomly allocated into four different groups: Group A: 15 women received two doses of 0.75 mg LNG taken 12 hours apart, with the first dose given on the morning of day ten of the menstrual cycle; Group B: 11 women received the same dose of LNG immediately after positive LH detection in urine; Group C: 11 women received the same dose of LNG 48 hours after positive detection of urinary LH and Group D: 8 women received the same dose of LNG in the late of follicular phase LH- (3 +/- 1).

Transvaginal ultrasound and serum LH were performed daily since the detection of urinary LH until follicular rupture. In addition, endometrial biopsies were taken – from all participants - at the day 9 after the LH peak.

Twelve participants of Group A did not ovulate and three did not ovulate but presented a significantly shorter luteal phase with lower progesterone levels.

In Groups B, C and D no modifications were noted in follicular phase length between treatment and control cycle.

In Groups B and C, no significant differences on either cycle length or luteal progesterone and estradiol concentrations were observed, while in Group D the cycle length was normal but progesterone luteal levels were significantly lower.

As to endometrial histology, the author concluded that in both control and treated cycles, weren't observed inflammatory reactions or other abnormal features.

Only twenty-four of the thirty-three biopsies were studied, because of insufficient tissue sample.

Marions et al. [47] studied twelve administered LNG-ECPs (0.75 mg twice, 12 h apart) to six women twice: the first time two days before ovulation; the second time two days after ovulation.

They evaluated both the urinary hormonal levels and on endometrial biopsy obtained six-seven days after LH surge.

LNG pre-ovulatory treatment inhibited the LH peak; the post-ovulatory treatment did not affect the cycle pattern, but the endometrium was normal only in three patients, out of phase in two and insufficient in one.
Subsequently Marions [48] administered the same treatment to seven women two days prior to ovulation (day -2; assessed by ultrasound). Both the urinary hormones and the destiny of the leading-follicle were evaluated. The treatment caused either a delay or an inhibition of the LH peak in all subjects. A significant delay in P4 levels and an initial suppression of E1 levels were also noted. The development of the leading follicle was either arrested or continued without signs of rupture.

This study indicates that, when used for EC, LNG administered prior to ovulation acts through an impaired ovulatory process and luteal function. Croxatto et al. [49] studied fifty-eight patients presumed healthy and normally cycling and evaluated the effects of the standard LNG regime (0.75 mg X 2, with a 12 hours interval between doses) or a single dose (1.50 mg) or placebo.

Participants were randomly assigned to three groups: one group received the first pill when the leading follicle reached a mean diameter of 12-14 mm (n=18); in the second group, it was given when the diameter of the follicle was 15-17 mm (n=22), the third group received the first pill when the follicle reached 18 mm.

As result, the spontaneous occurrence of either lack of follicular rupture or ovulatory dysfunction was rather high: up to 62% when given LNG-ECPs at a follicle diameter of 12-14 mm, 45% at 15-17 mm and 13% when the follicle diameter already reached > 18 mm.

Subsequently, Croxatto with Noè et al. [50] conclude that LNG-EC prevents pregnancy only when taken before fertilization of the ovum has occurred; they studied a cohort of women attending a family planning clinic for EC.

On the day of intake of LNG-EC and during five days follow-up, blood samples were taken for examination of luteinizing hormone, estradiol and progesterone concentrations, and vaginal ultrasound examinations were done for size of the leading follicle and/or corpus luteum. Of 388 women attending for LNG-EC, 122 women had intercourse on fertile cycle days according to ultrasound and endocrine findings.

At the time of LNG-EC intake, 87 women were in Days -5 to -1 and 35 women were in Day 0 (day of ovulation) or beyond. With the use of the probability of clinical pregnancy reported by Wilcox et al. [N Engl J Med 333 (1995) 1517-1521], expected numbers of pregnancies among the 87 and 35 women were 13 and 7, respectively, while 0 and 6 pregnancies, respectively, occurred.

Recently the International Consortium for Emergency Contraception (ICEC) in collaboration with the International Federation of Gynecologists and Obstetrics (FIGO) has updated its joint Statement "How do LNG-only emergency contraceptive pills (LNG ECPs) work to prevent pregnancy?".

The statement concludes that inhibition or delay of ovulation is LNG ECPs principal and possibly only mechanism of action; they still added that "Review of the evidence suggests that LNG ECPs cannot prevent implantation of fertilized egg [51,52]. The Statement conclusion isn't shared by other authors [44]. Mozzanega take in consideration and analyze the works [45-49] on which is based the Statement and he observe that only Marion's series [47,48] supports the Statement directly; in all the others the evidences are strikingly contrasting.

In the patients in which LNG really delayed or inhibited ovulation [45,46] were at the beginning of their fertile period when they received ECPs and so were the patients [49] treated when the leading-follicle had a mean diameter of 12-14 mm; unprotected sex in any previous day did likely occur when they were still infertile and the risk of pregnancy was likely null.
At last, he conclude that the number of the patients is really small and that the sample is not representative.

### 2.2.2 Impact on endometrium

As regard the LNG impact on endometrium, the attention of scientific literature is direct to investigate the LNG effects on the glycodelina endometrial expression and on glycodelina serum concentrations, both during peri-ovulatory midcycle [53,54] and at the time of LH surge [53,55].

Glycodelin is the mayor progesterone-regulated glycoprotein that is secreted into uterine luminal cavity by secretory/ decidualized endometrial glands [56]. Absence of glycodelin in the uterus during periovulatory midcycle is consistent with an open “fertile window”.

So, human endometrium contains no detectable glycodelin during the peri-ovulatory midcycle; the first appearence of glycodelin in endometrium is observed three days after the LH surge and its significant increase five-six days after LH surge, at the opening of the implantation window [57].

Glycodelin inhibits NK cell activity [58], monocytic cell chemotaxis [59], T-cell proliferation [60], and it induces T cell apoptosis [61] at the concentrations present in endometrial tissue and uterine fluid.

Glycodelin induced by local or systemic administration of progestogens may potentially reduce the fertilizing capacity of sperm in any phase of the menstrual cycle: it is the first endogenous glycoprotein that was found to potentially and dose-dependently inhibit binding of human sperm to the zona pellucida [62].

Duran et al. [53] examined serum glycodelin concentrations and endometrial expression during the luteal phase following oral administration of levonorgestrel (LNG) at different stages of the ovarian cycle.

She studied thirty women that were allocated into three Groups; Group 1 received LNG on days 3-4 before the LH surge, Group 2 received LNG at the time of LH rise and Group 3 received LNG 48 h after the LH surge.

Serum progesterone and glycodelin were measured daily during the luteal phase.

The treatment with LNG before the LH surge shortened by four days the lag period before appearance of glycodelin in serum during the luteal phase. Serum glycodelin levels steadily rose from day LH+ 2 to days LH+7-8 after which they declined.

In this way the hormonal EC with LNG, taken before the LH surge, alters endometrial glycodelin secretion in two important phases of the cycle: the first is in the fertile window during which an early increase of glycodelin secretion is interest for its antifertility activity; the second is in the phase of uterine receptivity in which reduced glycodelin expression may reflect weakened immunosuppressive microenvironment within the uterus at the time of implantation.

Subsequently Durand [54] studied thirty healthy sterilized women with normal ovarian function; each woman received LNG during the pre-ovulatory phase approximately two days before the LH surge.

Both LNG did not modify follicle rupture in 20 of 30 women and serum glycodelin concentrations significantly increased during the early and mid-luteal phases.

These results may represent an additional action of LNG in situation where the intervention did not interfere with ovulation.
Durand [53] and Palomino [55] studied the effects of LNG when its was administered on the day of LH surge without changes of the secretory pattern of glycodelin in serum in the luteal phase. Last, but not last, Meng et al. [63] studied a considerable number of markers of endometrial receptivity in women after LNG oral or vaginal administration. The two regimens of LNG caused either only minor or no alterations in markers of endometrial receptivity.

3-Mifepristone

The tradename of Mifepristone is Mifegyne.

3.1 Introduction

In 1980, Etienne-Emile Baulieu, working for the laboratories of Roussel Uclaf on progesterone derivatives discovered a potent anti-progestin, initially called RU-38486 (abbreviated in RU486) Mifepristone: is a steroid with affinity for the progesterone and glucocorticoid receptors, greater than that of natural compounds [64]. There are several uses of mifepristone. Administration of RU486 followed by the prostaglandin, misoprostol, has been used successfully in the medical termination of pregnancy. This is the best known application of this drug. However doses of Mifepristone are also effective as contraceptive [64]. Also single doses of the drug appear to be effective as emergency contraception [64-66], but it is only market in China [49,67, Tab1].

3.2 Mechanism of action

The effect of Mifepristone is on progesteron receptor. These belongs to a family of nuclear receptors includes receptors for the steroid hormones (glucocorticoid, mineralocorticoid, androgen, estrogen, and vitamin D) as well as for thyroid hormones and retinoids. These receptors are ligand-activated transcription factors with domains for DNA binding, hormone binding, and transactivation [68]. Specifically PR type A and B even if have similar DNA binding activities, they have different functional activities which depend on the cell type [65,69]. Studies carried out in PR-A and PR-B knockout mice have shown that PR-A is important for fertility, ovulation and uterine receptivity and mediates the anti-proliferative effect of progesterone in the follicular endometrium phase; Instead PR-B mediates differentiation and development of the mammary gland [70]. In the presence of mifepristone, receptors adopt an inactive conformation recruits corepressors such as nuclear receptor corepressor and silencing mediator of retinoic acid and thyroid hormone receptor. The result is a loss of transcriptional activity [71]. The action of Mifepristone in terminating early pregnancy, combinating with misoprostol, is due to its effects on the glucocorticoid [72] and progesterone [64] receptors located in the uterus. Both misoprostol and mifepristone induce cervical dilatation. Glucocorticoid receptor
blockade may result in an inappropriate cytokine response of the immune system [73]. The dose to achieve abortion is 200mg [74]. The contraceptive use of Mifepristone is due to its uterine and ovarian effects [75-77]. Instead emergency post-coital contraception probably is primarily due to inhibition of ovulation rather than inhibition of implantation [78]. It’s important to remark that the effects of Mifepristone vary depending on when the drugs is administer and the dose given.

3.2.1 Impact on ovulation

Administration of Mifepristone during the follicular phase of the menstrual cycle delays the estrogen rise and the luteinizing hormone (LH) surge. Specifically the treatment with 10mg prior to ovulation showed more a tendency to postpone ovulation [78]. The precise mechanism by which mifepristone affects the timing of ovulation is enigmatic. Infact Mifepristone has been shown not to alter the pattern of pulsatile secretion of LH [79,80] or pituitary responsiveness to gonadotrophin-releasing hormone (GnRH) [81]. The ability of mifepristone to perturb ovulation and FSH secretion is thought to be a result of the anti-progestogenic effect [78], even if seems that mifepristone significantly modified circulating levels of leptin. Evidences suggest that leptin is an important modulator of the timing of menstrual cycles. Infact in laboratory animals, leptin is known to regulate GnRH secretion via neuropeptide Y [82], and prevents suppression of gonadotrophin secretion [83]. In humans, leptin can regulate the nocturnal LH profile in the mid- to late follicular phase that precedes ovulation [84].

The adipocytes expression and release of leptin from adipose tissue is stimulated by glucocorticoids [85-87]. So Mifepristone, with is anti-glucocorticoid action, suppress leptin in fat. It was also demonstrated with cultured adipocytes [88]. There is the possibility that, in humans, suppression of circulating leptin concentrations following ingestion of mifepristone (10 mg) contributes to the subsequent and transient decrease in gonadotrophin secretion [76].

3.2.2 Impact on Endometrium

When a sufficient dose of mifepristone (10,50,600 mg) is given immediately after ovulation will significantly inhibit endometrial development [89,90]. It will also inhibit the expression of endometrial markers of endometrial receptivity such as leukemia inhibitory factor, integrins, and cyclooxygenase [91,92]. Particularly, a single dose administration of mifepristone produces several effects in the endometrium, myometrium and decidua. If implantation has occurred, the inhibition of transcription by the mifepristone-PR complex results in down-regulation of progesterone-dependent genes with decidual necrosis and detachment of products of conception [93]. It also directly promotes uterine contractions by increasing myometrial cell excitability, establishing gap junctions between cells and influx of calcium [94]. It also increases the release of prostaglandins by decidual cells [95]. Mifepristone may also affect tubal functions at high dose (200mg) after LH surge. The tubal microenvironment is of great importance; Infact the preimplanting embryo is exposed to a changing, hormonally regulated during its time in the tubal lumen. It is likely that in the
Fallopian tube the secretion of local factors, such as cytokines, is regulated by steroidal hormones; The inhibition of progesteron receptor mediated by mifepristone may impair the normal secretion of these cytokines [96]. Furthermore progesterone regulates tubal transport in vitro [97]; so a too rapid or too slow tubal transport could also be expected to cause desynchronization between the embryo and the tube, or the blastocyst and the endometrium [98,99]. Infact animal studies have previously shown accelerated tubal egg transport after mifepristone treatment [99]. Even if it is sure that in human, progesterone receptor concentration increased in tubal cells after Mifepristone administration, nevertheless the mechanism of action of these regimens when used for emergency contraception is not fully explained [96,98]. So Mifepristone can be used as emergency contraceptive as abortive/interception drug depending on dose and time of administration.

3-Ulipristal acetate

The trade name of ulipristal acetate(UPA)/CDB-2914 is EllaOne.

3.1 Introduction

Some trials show an higher failure rates when levonorgestrel is taken 48 hours or more after unprotected intercourse [37,100] so in May 2009, ulipristal acetate(UPA) was approved by EMEA as a safe and effective method of emergency contraception for use up to 5 days after unprotected sexual intercourse, on the basis of different trials [101-104] that included more than 4000 women.

UPA is a selective progesterone receptor modulator that inhibits or delays ovulation in women presenting 48-120 hours after unprotected intercourse when levonorgestrel efficacy markedly wanes. UPA has been shown to prevent ovulation and then fertilization even after the luteinizing hormone surge has begun [105].

UPA is orally active and taken as a single dose. So UPA is well accepted by women despite the insertion of an intrauterine device that many women find it unacceptable [106]. The major of women experience normal menses within 7 days of the expected date. Glasier [101] studied 1696 women. They received emergency contraception within 72 hours of sexual intercourse (UPA, n=844; levonorgestrel, n=852).
There were 15 pregnancies in the UPA group and 22 in the levonorgestrel group. In 203 women who received emergency contraception between 72 hours and 120 hours after sexual intercourse, there were three pregnancies, all in the levonorgestrel group.

This trial shows that UPA is non inferior to levonorgestrel for emergency contraception. This finding accords with the results of an earlier trial in which ulipristal acetate was at least as effective as levonorgestrel when taken up to 72 hours after sexual intercourse [102].

For women who present on the fourth or fifth day after sexual intercourse, UPA provides significant prevention of pregnancy whereas levonorgestrel did not and so for use beyond 72 hours and up 120 hours [101].

### 3.2 Mechanism of action

UPA exerts its pharmacological activity by binding progesterone receptors to produce an anti-progesterone contraceptive effect on ovary and on endometrium (endometrial thickness). These effects vary according to the timing of drug administration during the menstrual cycle [107].

In addition to its effect, UPA binds to glucocorticoid and androgen-receptor. However, its capacity as an antagonist in binding to these receptors is markedly lower than its anti-progestational activity [108].

#### 3.2.1 Impact on ovulation

The first studies to understand how the progesterone plays a key role during ovulation were done on mice. Mice lacking progesterone receptor gene fail to ovulate due to a defect in follicular rupture [108,109].

The biological effects of UPA vary according to the time of menstrual cycle that the drug is given and the doses. Singles doses of UPA administered during the mid-follicular phase suppress leading follicle growth, causing a dose-dependent delay in folliculogenesis. At higher doses, a new leading follicle is often recruited [110].

The effect of UPA at different follicular diameters and in relation to the LH peak and ovulation was studied. When given prior to LH rise, UPA inhibited 100% of follicular ruptures. When the size of the leading follicle was at least 18mm, follicular rupture failed to occur within the 5 and 6 days following UPA treatment in 20 (59%) and 15 (44%) subjects respectively. Even on the day of the LH peak UPA could delay ovulation for 24 to 48 hours after administration. Taken together these studies demonstrate that UPA may have a direct inhibitory effect on follicular rupture. This allows UPA to be effective even when
administered immediately before ovulation when LH has already started to rise, a time when use of LNG or Yuzpe is too late for ovulation inhibition [105].

Other authors studied pathways that modulate ovulation: gene expression profiling was performed using ovaries from mice subjected to gonadotropin induced superovulation in the presence and in the absence of UPA. Prominent among the genes that were down-regulated in response to UPA was endothelin-2, a potent vasoactive molecule. Endoteline-2 mRNA was transiently induced in mural granulosa cells of the preovulatory follicles immediately preceding ovulation. Furthermore, mice treated with an endothelin selective antagonists of endothelin receptor B exhibited a dramatic (> 85%) decline in the number of released oocytes [111].

Administering UPA before ovulation causes delayed follicle development and release, probably a result of suppression of estradiol levels. If the EC drug is taken during the LH peak, follicular rupture and ovum release may also be delayed [108].

3.2.2 Impact on endometrium

During the latter part of the menstrual cycle, UPA’s affect may be attributed to its ability to decrease endometrial thickness [112].

UPA, given at high or repeated doses have an effect on endometrial histology that could theoretically impair implantation of a fertilized oocyte [113].

Glasier believes that the dose of 30 mg of ulipristal acetate [101] was specifically titrated for emergency contraception on the basis of inhibition of ovulation and might be too low to inhibit implantation.

Fifty-six women with regular cycles were studied by Stratton et al. [113], using a single dose of UPA (10,50 or 100 mg) or placebo after ovulation and within 2 days of the LH surge. Four to six days later, a transvaginal ultrasound scan measured endometrial thickness, and an endometrial biopsy specimen was obtained. The endometrium was evaluated by immunohistochemical analysis for progesterone (P)–dependent markers.

UPA caused a significant dose-dependent decrease in endometrial thickness, an increase in glandular P receptors, and a decrease in peripheral node addressins. Estradiol and P levels and menstrual cycle timing were not altered.

The endometrial development was considered abnormal if there was > 2 days delay of pathologic dating compared with the chronologic day of cycle. The chronologic day of cycle was determined as the number of days from ultrasound-documented ovulation to biopsy.

Similar endometrial effects have been observed among those receiving mifepristone [114,115].

UPA also was associated with decreased expression of peripheral node addressins, which are important L-selectin ligands found on the surface of endothelial cells. Recent studies have
shown that L-selectin ligands are up-regulated during the implantation window, making the uterus more receptive to the trophoblast [116,117].

All these evidences would interfere with the implantation phase.

4-Discussions and conclusions

This review demonstrates that the hormonal products used in emergency contraception play different roles depending on the phase of the cycle during which they are administered. As things stand now, this conclusion allows to consider that in some cases the effect falls under hormonal contraception before the formation of the embryo and in some other cases the effect falls under the interruption of the development of an already formed embryo. Statistically, it is not possible to determine which is the dominant effect both because this evaluation depends on the exact knowledge of the ovulatory period of every woman when taking these hormones and because the studies carried on to date have not yet achieved a statistically significant number of cases.

It seems at any rate possible to consider that the discussion about these molecules may be a calm scientific debate on its biochemical and clinical aspects. A polemic about the possible harmful effects on the embryo does not seem helpful, since the international scientific community has already accepted the approach to the safe methods of the intentional abortion. This practice is indeed legal, safe and medically supervised in many countries. Finally, it is desirable that every woman is enabled to accurately know the effects of every drug at her disposal. In so doing she can knowingly choose whether using it or not only depending on her conscience and her needs.
References

[1] Diczfalussy E., Contraception and society, Eur J Contracept Reprod Health Care. 2002 Dec;7(4):199-209

[2] The E.S.H.R.E. Capri Workshop Group : Female contraception over 40, Human Reproduction Update, Vol.15, N.6, pp.599-612, 2009

[3] The E.S.H.R.E. Capri Workshop Group : Social Determinants of Human reproduction, Human Reproduction vol.16, N. 7 pp. 1518-1526,2001

[4] Dreyfus R., Histoire de la contraception in Serfaty D. : Contraception , Masson 1998

[5] Caroline Fee Raymond M Lee, Jane Ogden ) Young women's accounts of factors influencing their use and non-use of emergency contraception: in-depth interview study ; BMJ 325 : 1393 doi: 10.1136/bmj.325.7377.1393 (Published 14 December 2002)

[6] Potts M. , Bhiwandiwala : Birth Control : a world view in Filshie M. , Guillebaud: Contraception Science and practice, Butterwoths 1989

[7] Haspels A.A., Emergency Contraception: a Review, Contraception 1994; 50: 101-108.

[8] Yuzpe A.A., Turlow H.J., Ramzy I., Leyshon J.L.,: Post-coital Contraception. a Pilot Study, J Reprod Med 1974; 13: 53-58.

[9] Kesser E., Larranaga A., Parada J.: Postcoital Contraception with D-Norgestrel, Contraception 1973; 7: 367-379.

[10] Van Look P.F., Von Hertzen H.: Emergency Contraception, Br Med Bull 1993; 49: 158-170.

[11] Swahn M.L., Bygdeman M., Cekan S. et al. : The Effect of RU 486 Administered during the Early Luteal Phase on Bleeding Pattern,Hormonal Parameters and Endometrium, Hum Reprod 1990; 5: 402-408.

[12] World Health Organization : Emergency contraception : a guide for service delivery. WHO/FRH7FPP798.19.Geneva : WHO, 1998. www.who.int

[13] International Federation of Gynecology and Obstetrics (FIGO): Ethical Aspects Of Induced Abortion For Non Medical Reasons, 11;1998; http:// www.figo.org/default.asp?id=6057

[14] Internation Medical Advisory Panel, International Parenthood Federation IMAP: Statement of emergency contraception, IPPF Med Bull 2004; 38:13

[15] Centre for the Reproductive Rights Governments Worldwide put Emergency contraception in women Hands: A global review of law and policies. 9;2004.

[16] American College of Obstetricians and Gynecologist (ACOG):Statement on Contraceptive Methods 1998 A.
[17] E.C. Hughes (ed.), Committee of terminology, American College of Obstetricians and Gynecologists, Obstetric-Gynecologic Terminology, Philadelphia, Pennsylvania: FA Davis Company; 1972.

[18] Baulieu EE.: The Albert Lasker Medical Awards. RU-486 as an antiprogesterone steroid. From receptor to contragestion and beyond, JAMA. 1989 Oct 6;262(13):1808-14.

[19] Comunicato sulla “cosiddetta pillola del giorno dopo” , Pontificia Accademia per la vita, Città del Vaticano 31 Oct 2000

[20] Pescetto G., De Cecco L., Pecorari D., Ragni N.: Manuale di Ginecologia e Ostetricia , SEU, Roma 1996, pp. 823-824.

[21] World Health Organization : Levonorgestrel for Emergency contraception . WHO/RHR/FACT Sheet Geneva : WHO , October 2005.

[22] Schorge , John O., Schaffer , Joseph I.,Halvorson, Lisa M. et al.: First Trimester Abortion; Williams Gynecology ; McGrow Hill Medical; 2008

[23] Grimes D.A.: Emergency contraception Expanding opportunities For primary intervention, NEJM 1997; 337(15):1078-1079.

[24] Ford N.: When does human life begin ? Science, Government, Church, Pacifica 1988.

[25] Concise Medical Dictionary, Oxford Medical Publications, Oxford 1985.

[26] Reported in Planned Parenthood in Europe 1995; 24(2): 8.

[27] FDA (December 14, 2006). "Plan B: Questions and Answers, August 24, 2006, updated December 14, 2006". Archived from the original on 2007-09-29.

[28] Duramed Pharmaceuticals (September 2006). "Plan B Patient Pamphlet" , pp. 3. Archived from the original on 2008-02-27.

[29] Rahwan R.G., Morning-after birth control, Lancet 1995; 346: 252.

[30] The Congregation for the Doctrine of the Faith ; Dignitas Personae (Paragraph 23)2008; http://www.vatican.va/roman_curia/curia_info/publications/cfaith/documents/rc_con_cfaith_doc_2008_1208_dignitas-personae_en.html

[31] Durand M, del Carmen Cravioto M, Raymond EG, Durán-Sánchez O, De la Luz Cruz-Hinojosa M, Castell-Rodríguez A, Schiavon R, Larrea F.: On the mechanisms of action of short-term levonorgestrel administration in emergency contraception. Contraception. 2001 Oct;64(4):227-34.

[32] Coukell AJ, Balfour JA: Levonorgestrel subdermal implants. A review of contraceptive efficacy and acceptability. Drugs. 1998 Jun;55(6):861-87.

[33] Cheng L, Gulmezoglu AM, Piaggio G, Ezcurra E, Van Look PF.: Interventions for emergency contraception. Cochrane Database Syst; Rev 2008; 2: CD001324.
[34] Ho PC, Kwan MS.: A prospective randomized comparison of levonorgestrel with the Yuzpe regimen in post-coital contraception. Hum Reprod 1993; 3: 389–392.

[35] Rodrigues I, Grou F, Joly J.: Effectiveness of emergency contraceptive pills between 72 and 120 hours after unprotected sexual intercourse. Am J Obstet Gynecol 2001; 4: 531–537.

[36] Arowojolu AO, Okewole IA, Adekunle AO.: Comparative evaluation of the effectiveness and safety of two regimens of levonorgestrel for emergency contraception in Nigerians. Contraception 2002; 4: 269–273

[37] von Hertzen H, Piaggio G, Ding J, Chen J, Song S, Bartfai G, Ng E, Gemzell-Danielsson K, Oyunbileg A, Wu S et al.: Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. Lancet 2002; 9348: 1803–1810.

[38] Hamoda H, Ashok PW, Stalder C, Flett GM, Kennedy E, Templeton A.: A randomized trial of mifepristone (10 mg) and levonorgestrel for emergency contraception. Obstet Gynecol 2004; 6: 1307–1313.

[39] Turok DK.: The copper IUD and emergency contraception. Contraception 2011 Aug; 2011 Aug; 84(2): 205-6.

[40] Croxatto HB, Fernández SD.: Emergency contraception - a human rights issue. Best Pract Res Clin Obstet Gynaecol. 2006 Jun; 20(3): 311-22. Epub 2006 Feb 9

[41] Dunn S, Davis V; Society of Obstetricians and Gynaecologists of Canada.: Emergency contraception. Summary of the Society of Obstetricians and Gynaecologists of Canada's clinical practice guidelines. Can Fam Physician. 2001 Jun;47:1261-3, 1267-9.

[42] Croxatto HB, Devoto L, Durand M, Ezcurra E, Larrea F, Nagle C, Ortiz ME, Vantman D, Vega M, von Hertzen H.: Mechanism of action of hormonal preparations used for emergency contraception: a review of the literature. Contraception. 2001 Mar;63(3):111-21.

[43] Croxatto HB, Ortiz ME, Müller AL.: Mechanisms of action of emergency contraception. Steroids, 2003 Nov;68(10-13):1095-8.

[44] Bruno Mozzanega & Erich Cosmi.: How do levonorgestrel-only emergency contraceptive pills prevent pregnancy? Some consideration. Gynecological Endocrinology, 2010

[45] Dharani Hapanagama, Anna F. Glasier, David T. Baird.: The effects of peri-ovulatory administration of levonorgestrel on the menstrual cycle. Contraception 63 (2001) 123-129

[46] Marta Durand, Ma. Del Carmen Cravioto, Elizabeth G. Raymond, Ofelia Durán-Sánchez, Ma. De la Luz Cruz-Hinojosa, Andés Castell-Rodríguez, Raffaella Schiavon, Fernando Larrea.: On the mechanisms of action of short-term levonorgestrel administration in emergency contraception. Contraception 64 (2001) 227-234
[47] L. Marions, K. Hult, I. Lindell, X. Sun, B. Stäbi, K. Gemzell Danielsson.: Emergency contraception with mifepristone and levonorgestrel: mechanism of action. Obstet Gynecol. 2002 Jul; 100(1): 65-71

[48] L. Marions, S. Z. Cekan, M. Bygdeman, K. Gemzell-Danielsson.: Effect of emergency contraception with levonorgestrel or mifepristone on ovarian function. Contraception 2004 May; 69(5): 373-7.

[49] H. B. Croxatto, V. Brache, M. Pavez, L. Cochon, M. L. Forcelledo, F. Alvarez, R. Massai, A. Faundes, A. M. Salvatierra.: Pituitary-ovarian function following the standard levonorgestrel emergency contraceptive dose or a single 0.75 mg dose given on the days preceding ovulation. Contraception 70 (2004) 442-450

[50] Noé G, Croxatto HB, Salvatierra AM, Reyes V, Villarroel C, Muñoz C, Morales G, Retamales A.: Contraceptive efficacy of emergency contraception with levonorgestrel given before or after ovulation. Contraception. 2010 May;81(5):414-20. Epub 2010 Jan 27.

[51] International Consortium for Emergency Contraception (ICEC), International Federation of Gynecology & Obstetrics (FIGO). Statement on mechanism of action (October 2008)

[52] International Consortium for Emergency Contraception (ICEC), International Federation of Gynecology & Obstetrics (FIGO). Statement on mechanism of action (March 2011)

[53] Durand M, Seppala M, Cravioto Mdel C, Koistinen H, Koistinen R, González-Macedo J, Larrea F.: Late follicular phase administration of levonorgestrel as an emergency contraceptive changes the secretory pattern of glycodelin in serum and endometrium during the luteal phase of the menstrual cycle. Contraception. 2005 Jun;71(6):451-7.

[54] Durand M, Koistinen R, Chirinos M, Rodríguez JL, Zambrano E, Seppälä M, Larrea F.: Hormonal evaluation and midcycle detection of intrauterine glycodelin in women treated with levonorgestrel as in emergency contraception. Contraception. 2010 Dec;82(6):526-33. Epub 2010 Aug 4.

[55] Wilder Alberto Palomino, Paulina Kohen, Luigi Devoto.: A single midcycle dose of levonorgestrel similar to emergency contraceptive does not alter the expression of the L-selectin ligand or molecular markers of endometrial receptivity. Fertility and sterility Oct; 94(5)

[56] Seppala M, Taylor RN, Koistinen H, Koistinen R, Milgrom E.: Glycodelin: a major lipocalin protein of the reproductive axis with diverse actions in cell recognition and differentiation. Endocr Rev 2002; 23: 401–30.

[57] Brown SE, Mandelin E, Oehninger S, Toner JP, Seppala M, Jones Jr HW : Endometrial glycodelin-A expression in the luteal phase of stimulated ovarian cycles. Fertil Steril. 2000 74:130 –133
[58] Vigne JL, Hornung D, Mueller MD, Taylor RN: Purification and characterization of an immunomodulatory endometrial protein, glycodelin. J Biol Chem 2001 276:17101–17105

[59] Okamoto N, Uchida A, Takakura K, Kariya Y, Kanzaki H, Riittinen L, Koistinen R, Seppälä M, Mori: T Suppression by human placental protein 14 of natural killer cell activity. Am J Reprod Immunol 1991 26:137–142

[60] Rachmilewitz J, Riely GJ, Tykocinski ML: Placental protein 14 functions as a direct T-cell inhibitor. Cell Immunol 1999 191:26–33

[61] Mukhopadhyay D, Sundereshan S, Rao C, Karande: Placental protein 14 (PP14) induces apoptosis in T cells, but not in monocytes. J Biol Chem 2001 276: 28268 –28273

[62] Oehninger S, Coddington CC, Hodgen GD, Seppala M: Factors affecting fertilization: endometrial placental protein 14 reduces the capacity of human spermatozoa to bind to the human zona pellucida. Fertil Steril 1995 63:377–383

[63] C.-X. Meng, L. Marions, B. Bystrom, and K. Gemzell-Danielsson: Effects of oral and vaginal administration of levonorgestrel emergency contraception on markers of endometrial receptivity. Human Reproduction 2010 Vol.25, No.4 pp. 874–883

[64] Spitz IM: Mifepristone: where do we come from and where are we going? Clinical development over a quarter of a century. Contraception. 2010 Nov;82(5):442-52. Epub 2010 Feb 1.

[65] Wu S, Dong J, Cong J, Wang C, VonHertzen H, Godfrey EM.: Gestrinone compared with mifepristone for emergency contraception: a randomized controlled trial. Obstet Gynecol. 2010 Apr;115(4):740-4.

[66] Esteve JL, García R, Breto A, Llorente M.: Emergency contraception in Cuba with 10 mg of mifepristone. Eur J Contracept Reprod Health Care. 2007 Jun;12(2):162-7.

[67] Tang OS, Ho PC.: Clinical applications of mifepristone. Gynecol Endocrinol. 2006 Dec;22(12):655-9.

[68] Springwald A, Lattrich C, Skrzypczak M, Goerse R, Ortmann O, Treeck O.: Identification of novel transcript variants of estrogen receptor α, β and progesterone receptor gene in human endometrium. Endocrine. 2010 Jun;37(3):415-24. Epub 2010 Mar 25.

[69] Harrison DJ, Mitroka JG.: Defining reality: the potential role of pharmacists in assessing the impact of progesterone receptor modulators and misoprostol in reproductive health. Ann Pharmacother. 2011 Jan;45(1):115-9. Epub 2010 Dec 21.

[70] B. Mulac-Jericevic and O.M. Conneely: Reproductive tissue selective actions of progesterone receptors. Reproduction 128 (2004), pp. 139–146.

[71] B.L. Wagner, J.D. Norris, T.A. Knotts, N.L. Weigel and D.P. McDonnell: The nuclear corepressors NCoR and SMRT are key regulators of both ligand-and 8-bromo-cyclic AMP-
dependent transcriptional activity of the human progesterone receptor. *Mol Cell Biol* 18 (1998), pp. 1369–1378.

[72] Cervellati F, Pavan B, Lunghi L, Manni E, Fabbri E, Mascoli C, Biondi C, Patella A, Vesce F.: Betamethasone, progesterone and RU-486 (mifepristone) exert similar effects on connexin expression in trophoblast-derived HTR-8/SVneo cells. Reprod Fertil Dev. 2011;23(2):319-28.

[73] Miech RP.: Pathophysiology of mifepristone-induced septic shock due to Clostridium sordellii. Ann Pharmacother 2005;39:1483–8.

[74] Lievre M, Sitruk-Ware R.: Meta-analysis of 200 or 600 mg mifepristone in association with two prostaglandins for termination of early pregnancy. Contraception 2009;80:95–100.

[75] Agarwal M, Das V, Agarwal A, Pandey A, Srivastava D.: Evaluation of mifepristone as a once a month contraceptive pill. Am J Obstet Gynecol 2009

[76] Leminen R, Raivio T, Ranta S, Oehler J, von Hertzen H, Jänne OA, Heikinheimo O.: Late follicular phase administration of mifepristone suppresses circulating leptin and FSH mechanism(s) of action in emergency contraception? Eur J Endocrinol. 2005 Mar;152(3):411-8.

[77] Brown A, Cheng L, Lin S, Baird DT.: Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: a double-blind randomized control trial of 2 and 5 mg per day for 120 days. J Clin Endocrinol Metab 2002

[78] Marions Lena, Kjell Hultenby, Ingrid Lindell et al.: Emergency contraception with Mifepristone and Levonorgestrel: Mechanism of Action. The American College of Obstetrician and Gynecologist 2002

[79] Liu J, Garzo G, Morris S, Stunkel C, Ulmann A & Yen SS.: Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU486. Journal of Clinical Endocrinology and Metabolism 1987 65 1135–1140.

[80] Croxatto H, Salvatierra A, Fuentealba B & Leiva L.: Follicle stimulating hormone-granulosa cell axis involvement in the antifolliculotrophic effect of low dose mifepristone (RU486). Human Reproduction 1995 10 1987–1991.

[81] Baird DT, Thong KJ, Hall C & Cameron ST.: Failure of oestrogeninduced luteinizing hormone surge in women treated with mifepristone (RU 486) every day for 30 days. Human Reproduction 1995 10 2270–2276.

[82] Finn P, Cunningham M, Pau F, Spies H, Clifton D & Steiner R.: The stimulatory effect of leptin on the neuroendocrine reproductive axis of the monkey. Endocrinology 1998 139 4652–4662.

[83] Watanobe H.: Leptin directly acts within the hypothalamus to stimulate gonadotropin-releasing hormone secretion in vivo in rats. Journal of Physiology 2002 545 255–268.
[84] Licinio J, Negrao A, Mantzoros C, Kaklamani V, Wong ML, Bongiorno P, Mulla A, Cearnal L, Veldhuis J, Flier J, McCann S & Gold P.: Synchronicity of frequently sampled, 24-h concentrations of circulating leptin, luteinizing hormone, and estradiol in healthy women. PNAS 1998 95 2541–2546.

[85] Masuzaki H, Ogawa Y, Hosoda K, Miyawaki T, Hanaoka I, Hiraoka J, Yasuno A, Nishimura H, Yoshimasa Y, Nishi S & Nakao K.: Glucocorticoid regulation of leptin synthesis and secretion in humans: elevated plasma leptin levels in Cushing’s syndrome. Journal of Clinical Endocrinology and Metabolism 1997 82 2543–2547.

[86] Halleux CM, Saervais I, Reul BA, Detry R & Brichard SM.: Multihormonal control of ob gene expression and leptin secretion from cultured human visceral adipose tissue: increased responsiveness to glucocorticoids in obesity. Journal of Clinical Endocrinology and Metabolism 1998 83 902–910.

[87] Newcomer JW, Selke G, Melson AK, Gross J, Vogler GP & Dagogo-Jack S.: Dose-dependent cortisol-induced increases in plasma leptin concentration in healthy humans. Archives of General Psychiatry 1998 55 995–1000.

[88] Vicennati V, Vottero A, Friedman C & Papanicolaou DA.: Hormonal regulation of interleukin-6 production in human adipocytes. International Journal of Obesity 2002 26 905–911.

[89] Bygdeman M, Gemzell Danielsson K, Marions L, Swahn M-L.: Contraceptive use of anti-progesterone. Eur J Contracept Reprod Health Care 1999

[90] Xiao BL, von Herten H, Zhao H, Piaggio G.: A randomized doubleblind comparison of two single doses of mifepristone for emergency contraception. Hum Reprod 2002;17:3084–9.

[91] Gemzell Danielsson, K, Swahn M-L, Bygdeman M.: The effect of various doses of Mifepristone on endometrial leukaemia inhibitory factor expression in the midluteal phase-an immunohistochemical study. Hum Reprod 1997

[92] Mori D, Ogino N, Yonezawa T, Kawaminami M, Kurusu S.: Anti-ovulatory effects of RU486 and trilostane involve impaired cyclooxygenase-2 expression and mitotic activity of follicular granulosa cells in rats. Prostaglandins Other Lipid Mediat. 2011 Apr;94(3-4):118-23. Epub 2011 Mar 2.

[93] Zhu HX, Zhang WW, Zhuang YL, Huang LL.: Mifepristone as an anti-implantation contraceptive drug: roles in regulation of uterine natural killer cells during implantation phase. Am J Reprod Immunol. 2009 Jan;61(1):68-74.

[94] Bygdeman M, Swahn ML.: Progesterone receptor blockage. Effect on uterine contractility and early pregnancy. Contraception 1985;32:45–51.

[95] Bokström H, Norström A, Wiqvist N.: Cervical mucus concentration of prostaglandins E2 and F2 alpha after pretreatment with mifepristone in the first trimester of pregnancy. Prostaglandins. 1995 Jan;49(1):41-8.
[96] Christow A, Sun X, Gemzell-Danielsson K. Effect of mifepristone and levonorgestrel on expression of steroid receptors in the human Fallopian tube. Mol Hum Reprod. 2002 Apr;8(4):333-40.

[97] Mahmood T, Saridogan E, Smutna S, Habib AM, Djananbakhch O. The effect of ovarian steroids on epithelial ciliary beat frequency in the human Fallopian tube. Hum Reprod. 1998 Nov;13(11):2991-4.

[98] Gemzell-Danielsson K, Marions L. Mechanisms of action of mifepristone and levonorgestrel when used for emergency contraception. Hum Reprod Update. 2004 Jul-Aug;10(4):341-8. Epub 2004 Jun 10.

[99] Psychoyos A, Prapas I. Inhibition of egg development and implantation in rats after post-coital administration of the progesterone antagonist RU 486. J Reprod Fertil. 1987 Jul;80(2):487-91.

[100] Katzman D, Taddeo D. Emergency contraception. Paediatr Child Health. 2010 Jul;15(6):363-72

[101] Glasier A, Cameron S, Fine P et al. Ulipristal acetate versus Levonorgestrel for emergency contraception: a randomized non-inferiority trial and meta-analysis. Lancet 2010; 375:555-562

[102] Creinin MD, Schlaff W, Archer DF et al. Progesterone receptor modulator for emergency contraception: a randomized controlled trial. Obstet. Gynecol. 2006; 108: 1089-97

[103] Fine P, Mathé H, Ginde S et al. Ulipristal Acetate taken 48-120 hours after intercourse for emergency contraception; Obstetrics and Gynecology; Volume 1115, Numbers, Part 1, February 2010

[104] European Medicines Agency: European public assessment report (EPAR) EllaOne. EMEA/H/C/1027 April 2009

[105] Croxatto H, Brache V, Cochon L, Jesam C, Salvatierra AM, Levy D, et al; The effects of immediate preovulatory administration of 30mg ulipristal acetate o follicular rupture; 8th Congress of the European society of Gynecology; Rome, Italy, September 10-13, 2009

[106] Glasier A, Scorer J, Bigrig gA. Attitudes of women in Scotland to contraception: a qualitative study to explore acceptability of long acting methods. J Fam Plann Reprod Health Care 2008 34:213-17

[107] FDA : Background document for meeting of advisory committee for reproductive health drugs. NDA 22-474 ulipristal acetate(proposed trade name:ella HRA farma, june 17, 2010

[108] Gemzell-Danielsson K, Meng CX. Emergency contraception: potential role of ulipristal acetate. Int J Womens Health. 2010 Aug 9;2:53-61.

[109] Lydon JP, DeMayo FJ, Funk CR et al. Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev. 1995 Sep 15;9(18):2266-78.

Università degli Studi di Salerno
[110] Blithe DL, Nieman LK, Blye RP, Stratton P, Passaro M. Development of the selective progesterone receptor modulator CDB-2914 for clinical indications. Steroids. 2003 Nov;68(10-13):1013-7.

[111] Palanisamy GS, Cheon YP, Kim J, Kannan A, Li Q, Sato M, Mantena SR, Sitruk-Ware RL, Bagchi MK, Bagchi IC. A novel pathway involving progesterone receptor, endothelin-2, and endothelin receptor B controls ovulation in mice. Mol Endocrinol. 2006 Nov;20(11):2784-95. Epub 2006 Aug 3.

[112] Morrison, N.J: Watson Pharma, Inc.: ella (ulipristal acetate), package insert. August 2010

[113] Stratton P, Levens ED, Harton B et al.: Endometrial effects of a single early luteal dose of the selective early luteal dose of the selective progesterone receptor modulator CDB 2914 Fertil Steril 2009, feb 6.DOI: b10.1016/j.fertnstert.2008.12.057

[114] Gzemzell-Danielsson K, Hamberg M.:The effect of antiprogestin (RU 486) and prostaglandin biosynthesis inhibitor (naproxen) on uterine fluid prostaglandin F2 alpha concentrations. Hum Reprod. 1994 Sep;9(9):1626-30.

[115] Mäentausta O, Svalander P, Danielsson KG, Bygdeman M, Vihko R.:The effects of an antiprogestin, mifepristone, and an antiestrogen, tamoxifen, on endometrial 17 beta-hydroxysteroid dehydrogenase and progesterin and estrogen receptors during the luteal phase of the menstrual cycle: an immunohistochemical study. J Clin Endocrinol Metab. 1993 Oct;77(4):913-8.

[116] Foulk RA, Zdravkovic T, Genbacev O, Prakobphol A.: Expression of L-selectin ligand MECA-79 as a predictive marker of human uterine receptivity. J Assist Reprod Genet. 2007 Jul;24(7):316-21.

[117] Genbacev OD, Prakobphol A, Foulk RA, et al.: Trophoblast L-selectin-mediated adhesion at the maternal-fetal interface. Science. 2003 Jan 17;299(5605):405-8.
Table 1
Extract of “Dedicated Emergency Contraceptive Pills Worldwide”; available at www.not-2-late.com

| County          | Levonorgestrel ECPs                      | Ulipristal Acetate ECPs | Mifepristone ECPs |
|-----------------|-----------------------------------------|-------------------------|-------------------|
| Albania         | Norlevo 1,5mg Postinor2                 |                         |                   |
| Algeria         | Pregnon                                 |                         |                   |
| Andorra         | Norlevo 1,5mg                           |                         |                   |
| Angola          | Optinor                                 |                         |                   |
| Argentina       | Norgestrel-Max, Norgestrel Max unidose  |                         |                   |
| Armenia         | Escapelle, Postinor                     |                         |                   |
| Australia       | Levonelle 1*, Norlevo1,5* Postinor*     |                         |                   |
| Austria         | Postinor 1500*, Vikela* ellaOne         |                         |                   |
| Bahamas         | Optinor                                 |                         |                   |
| Bangladesh      | Postinor-2                              |                         |                   |
| Belgium         | Norlevo1,5 *, Postinor*, Postinor1500   |                         |                   |
| Bolivia         | Gianique, ImediatN, Impreviat, Pilem, Postinor-2, Pregnon, Tace | | |
| Bosnia and Herzegovina | Optinor                   |                         |                   |
| Botswana        | Pregnon                                 |                         |                   |
| Brazil          | Diad, Minipil2, Nogavride, Pilem,Poslov Postino Uno, Postiner, Pozato, Pozato Uni, PPMS, Prevyol | | |
| Bulgaria        | Escapelle*, Postinor Duo* ellaOne       |                         |                   |
| Cambodia        | Pregnon                                 |                         |                   |
| Cameroon        | Norlevo*, Optinor P2*                   |                         |                   |
| Canada §         | Norlevo 0,75**, PlanB**                 |                         |                   |
| Central Africa Republic | Optinor                   |                         |                   |
| Chile           | Escapel-1, Escapel-2, Optinor, PostDay, Pregnon | | |
| China           | AiWuYu (0,75mg)* AnTing (0,75mg)* AnTing (1,5mg)* BaoShi Ting(Postinor-2,0,75mg)* DanMei (0,75mg)* DanMei(1,5mg)* HuiTing(0,75mg)* HuiTing(1,5mg)*, JinXiao(0,75mg)*, Fu NaiEr(10mg)*, HouDingNuo(25mg), HuaDian (25mg),Si Mi An (25mg), BiYun (12,5mg)*,FuNaiEr(25mg),HouDing Nuo(10mg)*,HuaDian(10mg)*,Si MiAn(10mg)* | | |
| Country            | Contraceptives                                                                 |
|--------------------|-----------------------------------------------------------------------------|
| Colombia           | Escinor 1,5mg, PostDay, Postinor-1, Postinor-2, Pregnon, Tace               |
| Denmark            | Levonelle 1500, Norlevo 1,5mg                                               |
| Italy              | Levonelle, Norlevo 1,5mg, Unlevo 1500                                      |
| Ireland            | Levonelle 1500, Norlevo 1,5mg                                               |
| Lithuania          | Escapelle*, Postinor*                                                       |
| Luxemburg          | Norlevo 1,5*, Postinor*, Postinor 1,5*                                     |
| Mexico             | Alterna, Glanique, Ladiades 0,75, Ladiades 1,5, Postday, Postinor-2,       |
|                    | Postinor-2, Unidosis, Silogin 0,75mg, Silogin 1,5mg, Vika                  |
| Netherlands        | Norlevo 1,5**, Postinor 1500**                                              |
| Norway             | Norlevo 1,5**, Postinor 1,5**                                               |
| Portugal           | Norlevo 1,5*, Postinor 1500*                                               |
| Russia             | Escapelle, Escinor 0,75, Escinor 1,5                                        |
| Spain              | Norlevo 1,5*, Postinor*, Postinor 1,5*                                     |
| Sweden             | Norlevo 1,5*, Postinor 1,5*                                                |
| Switzerland        | Norlevo 1,5mg                                                               |
| United Kingdom     | Levonelle 1500, Levonelle OneStep*, Levonelle -1*, Levonelle -2            |
| United States of America § | NextChoice*, PlanB*, PlanB OneStep |

* available directly from a pharmacist without a prescription
** available over the counter

§ Emergency contraception is available from certain pharmacists without a prescription in Alaska, California, Hawaii, Maine, Massachusetts, New Hampshire, New Mexico, Washington State, and Vermont. Currently, there are different age restrictions for the EC products available in the US. Next Choice and Plan B One-Step are available OTC to women and men aged 17 or older. ella is available only by prescription to women of any age.